[HTML][HTML] Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments
HT Chifotides, S Verstovsek, P Bose - Cancers, 2023 - mdpi.com
Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …
[HTML][HTML] Recent advances in therapies for primary myelofibrosis
W Vainchenker, N Yahmi, V Havelange, C Marty… - Faculty …, 2023 - ncbi.nlm.nih.gov
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET)
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …
[HTML][HTML] A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
J Mascarenhas, AR Migliaccio, H Kosiorek… - Clinical Cancer …, 2023 - AACR
Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by
systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors …
systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors …
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
HO Ajufo, JA Waksal… - Therapeutic …, 2023 - journals.sagepub.com
Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies that
include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) …
include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) …
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis
D Capitanio, FR Calledda, V Abbonante, D Cattaneo… - Leukemia, 2024 - nature.com
Despite increased understanding of the genomic landscape of Myeloproliferative
Neoplasms (MPNs), the pathological mechanisms underlying abnormal megakaryocyte (Mk) …
Neoplasms (MPNs), the pathological mechanisms underlying abnormal megakaryocyte (Mk) …
[HTML][HTML] Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations …
R Mangione, C Giallongo, A Duminuco, E La Spina… - Antioxidants, 2024 - mdpi.com
To date, little is known concerning the circulating levels of biochemically relevant
metabolites (antioxidants, oxidative/nitrosative stress biomarkers, purines, and pyrimidines) …
metabolites (antioxidants, oxidative/nitrosative stress biomarkers, purines, and pyrimidines) …
[HTML][HTML] Melanocortin therapies to resolve fibroblast-mediated diseases
N Khodeneva, MA Sugimoto… - Frontiers in …, 2023 - frontiersin.org
Stromal cells have emerged as central drivers in multiple and diverse diseases, and
consequently, as potential new cellular targets for the development of novel therapeutic …
consequently, as potential new cellular targets for the development of novel therapeutic …
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN
E Reis, R Buonpane, H Celik, C Marty, A Lei… - Blood …, 2024 - ashpublications.org
Mutations in calreticulin (mutCALR) are the second most common drivers of
myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a …
myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a …
Characterization of non-driver mutations and identification of different outcomes and treatment strategies based on NGS results in myelofibrosis patients in different …
S Pepe - 2023 - iris.uniroma1.it
Myelofibrosis (MF), a chronic Ph-negative myeloproliferative neoplasm, is a clinically and
genetically heterogeneous disease. Beside driver mutations that represent the hallmark of …
genetically heterogeneous disease. Beside driver mutations that represent the hallmark of …